Trial
NCT05514717
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Day One Biopharmaceuticals, Inc.
Collaborators
—
Condition
HER2-positive Breast Cancer
Intervention
XMT-2056
Why stopped
Development discontinued.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-18